Base de dados : LILACS
Pesquisa : D04.210.500.054.079.429.824 [Categoria DeCS]
Referências encontradas : 601 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 61 ir para página                         

  1 / 601 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1292643
Autor: Bonilla-Sepúlveda, Oscar Alejandro.
Título: Ginecomastia: aspectos generales y etiológicos / Gynecomastia: general and etiological aspects
Fonte: Med. lab;25(1):393-408, 2021. tab, graf, ilus, fotografia.
Idioma: es.
Resumo: La ginecomastia es el crecimiento mamario benigno en el varón. Etiológicamente se clasifica en fisiológica y patológica. La ginecomastia fisiológica se presenta frecuentemente en ciertos periodos de la vida, como la época neonatal, puberal y senil. La patológica se asocia a múltiples factores, incluyendo los hormonales, los de origen tumoral, y al uso de ciertos medicamentos, entre otros; sin embargo, en muchos pacientes no se consigue identificar nunca la causa. La historia clínica y el examen físico son los pilares fundamentales que permiten orientar hacia la etiología, con el apoyo de pruebas de laboratorio e imagenología que permitan descartar una enfermedad clínica subyacente. En los casos moderados o severos, la cirugía es el tratamiento de elección. El objetivo del presente manuscrito es discutir algunos puntos de interés acerca de los aspectos más importantes relacionados con la ginecomastia, incluyendo la fisiopatología, la clínica y el diagnóstico, además de presentar las principales causas asociadas a esta condición. Por último, se describen los tipos de tratamiento disponibles para estos pacientes

Gynecomastia is the benign breast enlargement in males. Etiologically it is classified as physiological and pathological. Physiological gynecomastia is more frequently observed in newborns, adolescents, and in older men. Pathological gynecomastia is associated with multiple factors, including hormonal and of tumor origin, and to the use of certain medications, among other factors; however, in many patients the underlying cause may never be identified. Anamnesis and physical examination are the fundamental pillars that will guide towards the etiology, with the support of laboratory and imaging tests to rule out an underlying disease. In moderate or severe cases, surgery is the treatment of choice. The aim of this article is to discuss some key points about the most important aspects related to gynecomastia, including pathophysiology, symptoms and diagnosis, in addition to presenting the main causes associated with this condition. Finally, the types of treatment available for these patients are described
Descritores: Ginecomastia
-Testosterona
Estrogênios
Hipogonadismo
Androgênios
Tipo de Publ: Revisão
Responsável: CO373.9 - EDIMECO - Editora Médica Colombiana S.A.


  2 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1047325
Autor: Fonseca, Guilherme Wesley Peixoto da; Santos, Marcelo Rodrigues dos; Souza, Francis Ribeiro de; Negrão, Carlos Eduardo; Alves, Maria-Janieire de Nazaré Nunes.
Título: Testosterona e doença cardiovascular: do tratamento ao uso abusivo / Testosterone and cardiovascular disease: from treatment to abuse
Fonte: Rev. Soc. Cardiol. Estado de Säo Paulo;29(4,Supl):393-399, out.-dez. 2019. tab.
Idioma: pt.
Resumo: A testosterona, hormônio masculino com efeitos androgênicos e anabólicos, também exerce efeito sobre o leito vascular. Este hormônio promove vasodilatação através da liberação de óxido nítrico e modulação dos canais de cálcio que impacta a função endotelial. Em pacientes com doença arterial coronariana (DAC) e insuficiência cardíaca (IC), reduções nas concentrações de testosterona total (<300 ng/dL) estão relacionadas com maior mortalidade e severidade dessas doenças. Em pacientes com DAC, a reposição de testosterona (RT) tem relação com melhora do tônus vascular coronário e melhora do limiar de isquemia. Em pacientes com IC, os efeitos parecem estar mais relacionados à melhora da capacidade funcional, aumento na distância percorrida em testes funcionais, maior VO2máx, menor razão VE/VCO2, e melhora adicional da sensibilidade barorreflexa. No entanto, embora os efeitos da testosterona sobre o aumento de massa muscular e força muscular estejam bem estabelecidos na literatura, os efeitos dessa substância no sistema cardiovascular precisam ser elucidados. O aumento das concentrações de antígeno prostático específico da próstata tem sido constantemente discutido quando a RT é proposta no tratamento de pacientes com doenças cardiovasculares. Por se tratar de um hormônio com grande potencial anabólico, os efeitos do uso de quantidades suprafisiológicas de testosterona e seus análogos sobre as alterações cardiovasculares em jovens atletas têm sido estudados. Portanto, o objetivo dessa revisão é abordar os efeitos benéficos da RT em homens com hipogonadismo com DAC e IC, e mostrar os riscos relacionados com a prática indiscriminada do uso de anabolizantes em jovens sem deficiência de testosterona

Testosterone, the male hormone with androgenic and anabolic effects, also has an effect on the vascular bed. This hormone promotes vasodilation by releasing nitric oxide and calcium channel modulation that impacts endothelial function. In patients with coronary artery disease (CAD) and heart failure (HF), reductions in total testosterone concentrations (<300 ng/dL) are related to higher mortality and severity of these diseases. In patients with CAD, testosterone replacement (TR) is related to improved coronary vascular tone and improved ischemia threshold. In HF patients, the effects seem be more related to improved functional capacity, increased distance covered in functional tests, higher VO2max, lower LV/VCO2 ratio, and further improvement of baroreflex sensitivity. However, although the effects of testosterone on muscle mass gain and muscle strength are well established in the literature, the effects of testosterone on the cardiovascular system need to be elucidated. Increased prostate-specific prostate antigen concentrations have been constantly discussed when TR is proposed in the treatment of patients with cardiovascular disease. Because it is a hormone with great anabolic potential, the effects of supraphysiological amounts of testosterone and its analogues on cardiovascular disorders in young athletes have been studied. Therefore, the objective of this review is to address the beneficial effects of TR in men with hypogonadism with CAD and HF, and to show the risks related to anabolic steroids abuse in young people without testosterone deficiency
Descritores: Testosterona
Doenças Cardiovasculares/terapia
-Doença da Artéria Coronariana
Sistema Cardiovascular
Exercício Físico
Vasos Coronários
Insuficiência Cardíaca Diastólica
Hormônios
Hipogonadismo
Tipo de Publ: Revisão
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  3 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1249206
Autor: Chodari, Leila; Pourheydar, Bagher; Dariushnejad, Hassan; Jamshidi, Shahriyar; Khalaji, Naser; Ghorbanzadeh, Vajihe.
Título: Testosterone Combined with Voluntary Exercise Attenuates Diabetes-induced Pancreatic Apoptosis in Castrated Diabetic Rats Induced by HFD/STZ
Fonte: Braz. arch. biol. technol;64:e21200037, 2021. tab, graf.
Idioma: en.
Projeto: Urmia University of Medical Sciences.
Resumo: Abstract Increased apoptosis in the pancreas and beta cell death causes reduced insulin secretion in type 2 diabetes. This study was aimed to evaluate the effects of exercise training and testosterone administration on apoptosis marker (p53 protein) in the pancreas tissue in animal with diabetes. Type 2 diabetes was induced by high fat diet and injection of low dose STZ (35mg/kg; ip). After 2 months of treatment with testosterone (2mg/kg/day) or voluntary exercise alone or in combination, apoptosis (tunnel assay) and p53 protein (ELISA method) were measured. Testosterone and exercise decreased the blood glucose, HbA1c levels, HOMA-IR, p53 protein expression and increased insulin level in treated diabetic and diabetic castrated groups. Simultaneous treatment of these groups with testosterone together voluntary exercise had an additive effect on reducing p53 expression, blood glucose, HbA1c levels, HOMA-IR and subsequently decreasing apoptosis. Our results suggest that the apoptosis decreasing effect of testosterone and voluntary exercise is associated with the reduced levels of blood glucose, HbA1c and HOMA-IR that subsequently decreased the expression of p53 level.
Descritores: Testosterona/uso terapêutico
Exercício Físico
Diabetes Mellitus Tipo 2/terapia
-Apoptose
Controle Glicêmico
Limites: Animais
Ratos
Responsável: BR1.1 - BIREME


  4 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-978115
Autor: Adauy, Arlette; Sandoval, Jorge; Ríos, Rafael; Cartes, Alejandra; Salinas, Hugo.
Título: Terapia hormonal en persona transgénero según world professional association for transgender health (WPATH) () y guías clinicas de la endocrine society. () / Hormone therapy in transgender person according to world professional association for transgender health (WPATH) and clinical guidelines of the endocrine society
Fonte: Rev. chil. obstet. ginecol. (En línea);83(4):426-441, 2018. tab.
Idioma: es.
Resumo: RESUMEN La identidad de género es la percepción intrínseca de una persona de ser hombre, mujer o alguna alternativa de género. Las personas transgénero perciben estar en un cuerpo equivocado, ya que se sienten del sexo opuesto al biológico. Cuando esta incongruencia entre identidad de género y el fenotipo físico del sexo asignado, genera gran angustia, ansiedad y malestar persistente, se denomina disforia de género. Se estima que el 0,4%- 1.3% de la población mundial experimentan distintos grados de Disforia de Género. (3), no todas las personas con disforia de género tienen las mismas necesidades, por lo que la evaluación del objetivo personal para lograr bienestar es muy importante. Todas las intervenciones médicas conllevan riesgos, por lo que, la comprensión de éstos últimos, la adherencia y el manejo por profesionales capacitados los minimiza. En Revista de la Sociedad Chilena de Obstetricia y Ginecología Infantil y de la Adolescencia, recientemente hemos publicado dos artículos de revisión sobre la introducción a la Hormonoterapia en personas transgénero, objetivos de la terapia, transición en la adolescencia, y la transición masculino a femenino, por lo que éste escrito se concentrará sólo en los Riesgos de la Terapia Hormonal en la transición. (4,5)

SUMMARY Gender identity is the intrinsic perception of a person to be a man, woman or some gender alternative. Transgender people feel that they are in the wrong body, since they feel the opposite sex to the assigned. When this incongruence between gender identity and the physical phenotype generates great anguish, anxiety and persistent discomfort, it is called gender dysphoria. It is estimated that 0.4% −1.3% of the world population experience different degrees of Gender Dysphoria. (3), and not all people with gender dysphoria have the same needs, so the evaluation of the personal goal to achieve well-being is very important. All medical interventions involve risks, so the understanding of the latter, adherence and management by trained professionals minimizes them. In the Journal of the Chilean Society of Obstetrics and Child and Adolescent Gynecology, we have recently published two review articles on the introduction to Hormonotherapy in transgender people, objectives of therapy, transition in adolescence, and the male to female transition, so this writing will focus only on the Risks of Hormonal Therapy in the transition. (4,5)
Descritores: Testosterona/uso terapêutico
Terapia de Reposição Hormonal/efeitos adversos
Pessoas Transgênero
Disforia de Gênero
Ginecologia
Androgênios/uso terapêutico
Obstetrícia
-Transexualidade/epidemiologia
Procedimentos de Readequação Sexual
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CL126.2 - Biblioteca Médica Dr. Profesor Hernán Alessandri R.


  5 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-796893
Autor: Fiamegos, Alexandros; Varkarakis, John; Kontraros, Michael; Karagiannis, Andreas; Chrisofos, Michael; Barbalias, Dimitrios; Deliveliotis, Charalampos.
Título: Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
Fonte: Int. braz. j. urol;42(5):925-931, Sept.-Oct. 2016. tab.
Idioma: en.
Resumo: Abstract Introduction: Data from animal, clinical and prevention studies support the role of androgens in prostate cancer growth, proliferation and progression. Results of serum based epidemiologic studies in humans, however, have been inconclusive. The present study aims to define whether serum testosterone can be used as a predictor of a positive second biopsy in males considered for re-biopsy. Material and Methods: The study included 320 men who underwent a prostatic biopsy in our department from October 2011 until June 2012. Total testosterone, free testosterone, bioavailable testosterone and prostate pathology were evaluated in all cases. Patients undergoing a second biopsy were identified and biopsy results were statistically analyzed. Results: Forty men (12.5%) were assessed with a second biopsy. The diagnosis of the second biopsy was High Grade Intraepithelial Neoplasia in 14 patients (35%) and Prostate Cancer in 12 patients (30%). The comparison of prostatic volume, total testosterone, sex hormone binding globulin, free testosterone, bioavailable testosterone and albumin showed that patients with cancer of the prostate had significantly greater levels of free testosterone (p=0.043) and bioavailable T (p=0.049). Conclusion: In our study, higher free testosterone and bioavailable testosterone levels were associated with a cancer diagnosis at re-biopsy. Our results indicate a possible role for free and bioavailable testosterone in predicting the presence of prostate cancer in patients considered for re-biopsy.
Descritores: Neoplasias da Próstata/patologia
Neoplasias da Próstata/sangue
Testosterona/sangue
Biópsia/métodos
Antígeno Prostático Específico/sangue
Neoplasia Prostática Intraepitelial/patologia
Neoplasia Prostática Intraepitelial/sangue
-Próstata/patologia
Padrões de Referência
Valores de Referência
Biomarcadores Tumorais/sangue
Valor Preditivo dos Testes
Fatores de Risco
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  6 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-782851
Autor: Yamaçake, K. G. R; Cocuzza, M; Torricelli, F. C. M; Tiseo, B. C; Frati, R; Freire, G. C; Antunes, A. A; Srougi, M.
Título: Impact of body mass index, age and varicocele on reproductive hormone profile from elderly men
Fonte: Int. braz. j. urol;42(2):365-372, Mar.-Apr. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To study the impact of obesity, age and varicocele on sexual hormones fof adult and elderly men. Materials and Methods: 875 men who were screened for prostate cancer were enrolled in this study. Data recorded comprised age, body mass index (BMI), serum levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), luteinizing hormone (LH) and follicular stimulating hormone (FSH). Patients were divided in groups according to their BMI in underweight, normal weight, overweight and obese grades 1, 2 or 3. First, it was studied the association between age, BMI, and hormone profile. Then, clinical varicocele was evaluated in 298 patients to assess its correlation to the others parameters. Results: Obese patients had lower levels of TT, FT and SHBG (p<0.001) compared to underweight or normal weight patients. There were no differences in age (p=0.113), FSH serum levels (p=0.863) and LH serum levels (p=0.218) between obese and non-obese patients. Obese grade 3 had lower levels of TT and FT compared to obese grade 1 and 2 (p<0.05). There was no difference in the SHBG levels (p=0.120) among obese patients. There was no association between varicocele and BMI; and varicocele did not impact on testosterone or SHBG levels. Conclusions: Men with higher BMI have a lower serum level of TT, FT and SHBG. The presence of clinical varicocele as well as its grade has no impact on hormone profile in elderly men.
Descritores: Testosterona/sangue
Varicocele/sangue
Globulina de Ligação a Hormônio Sexual/análise
Hormônio Luteinizante/sangue
Hormônio Foliculoestimulante/sangue
Obesidade/sangue
-Valores de Referência
Varicocele/fisiopatologia
Índice de Gravidade de Doença
Índice de Massa Corporal
Estudos Transversais
Fatores Etários
Estatísticas não Paramétricas
Pessoa de Meia-Idade
Obesidade/fisiopatologia
Limites: Humanos
Masculino
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  7 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-828942
Autor: Marconi, Marcelo; Souper, Renato; Hartmann, Jonathan; Alvarez, Matías; Fuentes, Ignacio; Guarda, Francisco J.
Título: Clomiphene citrate treatment for late onset hypogonadism: rise and fall
Fonte: Int. braz. j. urol;42(6):1190-1194, Nov.-Dec. 2016. graf.
Idioma: en.
Resumo: ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.
Descritores: Testosterona/sangue
Clomifeno/uso terapêutico
Antagonistas de Estrogênios/uso terapêutico
Hipogonadismo/terapia
-Hormônio Luteinizante/sangue
Estudos Prospectivos
Seguimentos
Resultado do Tratamento
Clomifeno/administração & dosagem
Antagonistas de Estrogênios/administração & dosagem
Hormônio Foliculoestimulante/sangue
Hipogonadismo/cirurgia
Pessoa de Meia-Idade
Limites: Humanos
Adulto
Idoso
Responsável: BR1.1 - BIREME


  8 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-892932
Autor: Ergün, Osman; Koşar, Pinar Aslan; Onaran, İbrahim; Darici, Hakan; Koşar, Alim.
Título: Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection
Fonte: Int. braz. j. urol;43(6):1167-1175, Nov.-Dec. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model. Materials and Methods: 40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex. Results: Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%. Conclusion: Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in prostatic benign hyperplasia that needs to be verified in large randomized human experimental studies.
Descritores: Hiperplasia Prostática/tratamento farmacológico
Terapia Genética/métodos
Muramidase/genética
Toxinas Botulínicas Tipo A/uso terapêutico
-Hiperplasia Prostática/induzido quimicamente
Testosterona
Ratos Wistar
Modelos Animais de Doenças
Limites: Animais
Masculino
Ratos
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  9 / 601 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Costa, Waldemar S
Texto completo
Id: biblio-892904
Autor: Felix-Patrício, Bruno; Miranda, Alexandre F; Medeiros J, Jorge L; Gallo, Carla B. M; Gregório, Bianca M; Souza, Diogo B. de; Costa, Waldemar S; Sampaio, Francisco J. B.
Título: The prostate after castration and hormone replacement in a rat model: structural and ultrastructural analysis
Fonte: Int. braz. j. urol;43(5):957-965, Sept.-Oct. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To evaluate if late hormonal replacement is able to recover the prostatic tissue modified by androgenic deprivation. Materials and Methods: 24 rats were assigned into a Sham group; an androgen deficient group, submitted to bilateral orchiectomy (Orch); and a group submitted to bilateral orchiectomy followed by testosterone replacement therapy (Orch+T). After 60 days from surgery blood was collected for determination of testosterone levels and the ventral prostate was collected for quantitative and qualitative microscopic analysis. The acinar epithelium height, the number of mast cells per field, and the densities of collagen fibers and acinar lumen were analyzed by stereological methods under light microscopy. The muscle fibers and types of collagen fibers were qualitatively assessed by scanning electron microscopy and polarization microscopy. Results: Hormone depletion (in group Orch) and return to normal levels (in group Orch+T) were effective as verified by serum testosterone analysis. The androgen deprivation promoted several alterations in the prostate: the acinar epithelium height diminished from 16.58±0.47 to 11.48±0.29μm; the number of mast cells per field presented increased from 0.45±0.07 to 2.83±0.25; collagen fibers density increased from 5.83±0.92 to 24.70±1.56%; and acinar lumen density decreased from 36.78±2.14 to 16.47±1.31%. Smooth muscle was also increased in Orch animals, and type I collagen fibers became more predominant in these animals. With the exception of the densities of collagen fibers and acinar lumen, in animals receiving testosterone replacement therapy all parameters became statistically similar to Sham. Collagen fibers density became lower and acinar lumen density became higher in Orch+T animals, when compared to Sham. This is the first study to demonstrate a relation between mast cells and testosterone levels in the prostate. This cells have been implicated in prostatic cancer and benign hyperplasia, although its specific role is not understood. Conclusion: Testosterone deprivation promotes major changes in the prostate of rats. The hormonal replacement therapy was effective in reversing these alterations.
Descritores: Próstata/patologia
Próstata/ultraestrutura
Testosterona/sangue
Orquiectomia
Terapia de Reposição Hormonal
Androgênios/deficiência
-Próstata/efeitos dos fármacos
Ratos Sprague-Dawley
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  10 / 601 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-840825
Autor: Karabakan, Mehmet; Keskin, Ercument; Akdemir, Serkan; Bozkurt, Aliseydi.
Título: Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction
Fonte: Int. braz. j. urol;43(2):317-324, Mar.-Apr. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01). Conclusion A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.
Descritores: Ereção Peniana/efeitos dos fármacos
Ejaculação/efeitos dos fármacos
Inibidores da Fosfodiesterase 5/administração & dosagem
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Ejaculação Precoce/tratamento farmacológico
Tadalafila/administração & dosagem
Disfunção Erétil/tratamento farmacológico
-Testosterona/sangue
Fatores de Tempo
Glicemia/análise
Ereção Peniana/fisiologia
Esquema de Medicação
Colesterol/sangue
Inquéritos e Questionários
Estudos Retrospectivos
Resultado do Tratamento
Estatísticas não Paramétricas
Ejaculação/fisiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Ejaculação Precoce/fisiopatologia
Disfunção Erétil/fisiopatologia
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Adulto
Idoso
Responsável: BR1.1 - BIREME



página 1 de 61 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde